GeneDx expects to exceed revised 2023 revenue guidance

 Sees fourth quarter 2023 revenue from continuing operations1 of more than $57M with at least 63% year-over-year revenue growth for exome and genome test revenue

Reduced fourth quarter 2023 cash burn 51% year-over-year and 21% sequentially

Ending December 31, 2023 cash position of at least $131 million

Reiterating the path to profitability in 2025

https://www.globenewswire.com/news-release/2024/01/08/2805483/0/en/GeneDx-Announces-Preliminary-2023-Financial-Results.html